|
1
|
Wang Y, Liu DH, Xu LP, Liu KY, Chen H,
Zhang XH, Chen YH, Han W, Wang FR, Wang JZ, et al: Prevention of
relapse using granulocyte CSF-primed PBPCs following
HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in
patients with advanced-stage acute leukemia: A retrospective
risk-factor analysis. Bone Marrow Transplant. 47:1099–1104. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hasskarl J, Zerweck A, Wäsch R, Ihorst G,
Bertz H and Finke J: Induction of graft versus malignancy effect
after unrelated allogeneic PBSCT using donor lymphocyte infusions
derived from frozen aliquots of the original graft. Bone Marrow
Transplant. 47:277–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Cheikh J, Crocchiolo R, Furst S,
Ladaique P, Castagna L, Faucher C, Granata A, Oudin C, Lemarie C,
Calmels B, et al: Lenalidomide plus donor-lymphocytes infusion
after allogeneic stem-cell transplantation with reduced-intensity
conditioning in patients with high-risk multiple myeloma. Exp
Hematol. 40:521–527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Deol A and Lum LG: Role of donor
lymphocyte infusions in relapsed hematological malignancies after
stem cell transplantation revisited. Cancer Treat Rev. 36:528–538.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McLarnon A, Piper KP, Goodyear OC, Arrazi
JM, Mahendra P, Cook M, Clark F, Pratt G, Craddock C and Moss PA:
CD8(+) T-cell immunity against cancer-testis antigens develops
following allogeneic stem cell transplantation and reveals a
potential mechanism for the graft-versus-leukemia effect.
Haematologica. 95:1572–1578. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oettel KR, Wesly OH, Albertini MR, Hank
JA, Iliopolis O, Sosman JA, Voelkerding K, Wu SQ, Clark SS and
Sondel PM: Allogeneic T-cell clones able to selectively destroy
Philadelphia chromosome-bearing (Ph1+) human leukemia lines can
also recognize Ph1- cells from the same patient. Blood.
83:3390–3402. 1994.PubMed/NCBI
|
|
7
|
Mackinnon S, Papadopoulos EB, Carabasi MH,
Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH,
Gillio AP and Kernan NA: Adoptive immunotherapy evaluating
escalating doses of donor leukocytes for relapse of chronic myeloid
leukemia after bone marrow transplantation: Separation of
graft-versus-leukemia responses from graft-versus-host disease.
Blood. 86:1261–1268. 1995.PubMed/NCBI
|
|
8
|
Dazzi F, Szydlo RM, Cross NC, Craddock C,
Kaeda J, Kanfer E, Cwynarski K, Olavarria E, Yong A, Apperley JF
and Goldman JM: Durability of responses following donor lymphocyte
infusions for patients who relapse after allogeneic stem cell
transplantation for chronic myeloid leukemia. Blood. 96:2712–2716.
2000.PubMed/NCBI
|
|
9
|
British Committee for Standards in
Haematology, ; Milkins C, Berryman J, Cantwell C, Elliott C, Haggas
R, Jones J, Rowley M, Williams M and Win N: Guidelines for
pre-transfusion compatibility procedures in blood transfusion
laboratories. British Committee for Standards in Haematology.
Transfus Med. 23:3–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McGuirk JP, Seropian S, Howe G, Smith B,
Stoddart L and Cooper DL: Use of rituximab and irradiated
donor-derived lymphocytes to control Epstein-Barr virus-associated
lymphoproliferation in patients undergoing related haplo-identical
stem cell transplantation. Bone Marrow Transplant. 24:1253–1258.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsirigotis P, Resnick IB, Kapsimalli V,
Dray L, Psarra E, Samuel S, Spyridonidis A, Konsta E, Vikentiou M,
Or R, et al: Irradiated mononuclear cells express significant in
vitro cytotoxic activity: Promise for in vivo clinical efficacy of
irradiated mismatched donor lymphocytes infusion. Immunotherapy.
6:409–417. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reynolds JT, Watkins JM, Dufan TA and
Kubsad SS: Irradiation of donor mononuclear cells for treatment of
chemorefractory metastatic solid cancers: A community-based immune
transplant pilot study. Cancer Res Treat. 44:133–141. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu BY, Song CY, Guo KY, Yan DA, Yang YL,
Xiao LL and Wu GX: Treatment of malignant hematologic diseases by
peripheral blood stem cell transplantation combined with halotype
lymphocyte infusion. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
11:287–291. 2003.(In Chinese). PubMed/NCBI
|
|
14
|
Pierelli L, Menichella G, Paoloni A,
Teofili L, Sica S, Foddai ML, Rossi PL, Leone G, Mango G and Bizzi
B: Collection of peripheral blood stem cells using an automated
discontinuous flow blood cell separator. Haematologica. 75 Suppl
1:S29–S32. 1990.
|
|
15
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of
Tumors of the Haematopoietic and Lymphoid Tissues. 4th edition.
IARC Press; Lyon: 2008
|
|
16
|
Kolb HJ, Schmid C, Barrett AJ and Schendel
DJ: Graft-versus-leukemia reactions in allogeneic chimeras. Blood.
103:767–776. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xia G, Truitt RL and Johnson BD:
Graft-versus-leukemia and graft-versus-host reactions after donor
lymphocyte infusion are initiated by host-type antigen-presenting
cells and regulated by regulatory T cells in early and long-term
chimeras. Biol Blood Marrow Transplant. 12:397–407. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kolb HJ: Graft-versus-leukemia effects of
transplantation and donor lymphocytes. Blood. 112:4371–4383. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stern M, Passweg JR, Meyer-Monard S, Esser
R, Tonn T, Soerensen J, Paulussen M, Gratwohl A, Klingebiel T,
Bader P, et al: Pre-emptive immunotherapy with purified natural
killer cells after haploidentical SCT: A prospective phase II study
in two centers. Bone Marrow Transplant. 48:433–438. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yun HD and Waller EK: Finding the sweet
spot for donor lymphocyte infusions. Biol Blood Marrow Transplant.
19:507–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Porter DL, Collins RH Jr, Shpilberg O,
Drobyski WR, Connors JM, Sproles A and Antin JH: Long-term
follow-up of patients who achieved complete remission after donor
leukocyte infusions. Biol Blood Marrow Transplant. 5:253–261. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liga M, Triantafyllou E, Tiniakou M,
Lambropoulou P, Karakantza M, Zoumbos NC and Spyridonidis A: High
alloreactivity of low-dose prophylactic donor lymphocyte infusion
in patients with acute leukemia undergoing allogeneic hematopoietic
cell transplantation with an alemtuzumab-containing conditioning
regimen. Biol Blood Marrow Transplant. 19:75–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bar M, Sandmaier BM, Inamoto Y, Bruno B,
Hari P, Chauncey T, Martin PJ, Storb R, Maloney DG, Storer B and
Flowers ME: Donor lymphocyte infusion for relapsed hematological
malignancies after allogeneic hematopoietic cell transplantation:
Prognostic relevance of the initial CD3+ T cell dose. Biol Blood
Marrow Transplant. 19:949–957. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levine JE, Braun T, Penza SL, Beatty P,
Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt
S, et al: Prospective trial of chemotherapy and donor leukocyte
infusions for relapse of advanced myeloid malignancies after
allogeneic stem-cell transplantation. J Clin Oncol. 20:405–412.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Waller EK, Ship AM, Mittelstaedt S, Murray
TW, Carter R, Kakhniashvili I, Lonial S, Holden JT and Boyer MW:
Irradiated donor leukocytes promote engraftment of allogeneic bone
marrow in major histocompatibility complex mismatched recipients
without causing graft-versus-host disease. Blood. 94:3222–3233.
1999.PubMed/NCBI
|
|
26
|
Nikiforow S and Alyea EP: Maximizing GVL
in allogeneic transplantation: Role of donor lymphocyte infusions.
Hematology Am Soc Hematol Educ Program. 2014:570–575.
2014.PubMed/NCBI
|
